Previous 10 | Next 10 |
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Dr. Thomas H...
Significant investment demonstrates confidence in Spring Bank’s novel development programs Extends Spring Bank’s cash runway beyond the end of 2021 Accelerates HBV antisense and STING antagonist development programs HOPKINTON, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE)...
HOPKINTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entere...
Spring Bank Pharma (NASDAQ: SBPH ): Q2 GAAP EPS of -$0.28 beats by $0.28 . More news on: Spring Bank Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOPKINTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced its financial resu...
HOPKINTON, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, announced that its Investigational...
- First Patient Dosed Ahead of Schedule in Inarigivir 400mg CATALYST 2 Trial - First Patient Completes Dosing in Inarigivir 400mg Intra-Hepatic Liver Biopsy Study - Ongoing Inarigivir + Tenofovir Alafenamide 25mg Co-Administration Trial Expanded to ...
HOPKINTON, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it has entere...
AbbVie (NYSE: ABBV ) has acquired Kirkland, WA-based Mavupharma , a privately held biopharma outfit developing cancer treatments based on the STING (STimulator on INterferon Genes) signaling pathway that plays a key role in the generation of an immune response to tumors. Financial te...
HOPKINTON, Mass., July 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Pamela Klein,...
News, Short Squeeze, Breakout and More Instantly...
Spring Bank Company Name:
SBPH Stock Symbol:
NASDAQ Market:
F-star Therapeutics Completes Combination with Spring Bank Pharmaceuticals To Commence Trading November 23 on Nasdaq: FSTX PR Newswire CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, England and CAMBRIDGE, Mass. , Nov. 20, 2020 /PRN...
CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics 1-for-4 Reverse Stock Split to be Effective November 23, 2020 PR Newswire HOPKINTON, Mass., Nov. 20, 2020 HOPKINTON, Mass. , Nov. 20, 2020 /PRNe...
HOPKINTON, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, announced that at its special meeting of stock...